Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
Authors
Keywords
-
Journal
NATURE
Volume 523, Issue 7560, Pages 352-356
Publisher
Springer Nature
Online
2015-05-22
DOI
10.1038/nature14430
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
- (2014) Patricia A.J. Muller et al. CANCER CELL
- Ganetespib and HSP90: Translating Preclinical Hypotheses into Clinical Promise
- (2014) D. A. Proia et al. CANCER RESEARCH
- Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling
- (2014) Susann Weissmueller et al. CELL
- Targeting tumour-supportive cellular machineries in anticancer drug development
- (2014) Matthias Dobbelstein et al. NATURE REVIEWS DRUG DISCOVERY
- Drugging the p53 pathway: understanding the route to clinical efficacy
- (2014) Kian Hoe Khoo et al. NATURE REVIEWS DRUG DISCOVERY
- UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib
- (2014) H Landmann et al. Cell Death & Disease
- Histone deacetylase inhibitors
- (2013) Marije Slingerland et al. ANTI-CANCER DRUGS
- Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis
- (2013) W Hanel et al. CELL DEATH AND DIFFERENTIATION
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer
- (2013) M. A. Socinski et al. CLINICAL CANCER RESEARCH
- Geldanamycin and its derivatives as Hsp90 inhibitors
- (2012) Magdalena Gorska Frontiers in Bioscience-Landmark
- Drastic Effect of GermlineTP53Missense Mutations in Li-Fraumeni Patients
- (2012) Yasmine Zerdoumi et al. HUMAN MUTATION
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones
- (2011) David Siegel et al. BIOCHEMICAL PHARMACOLOGY
- Multiple Stress Signals Activate Mutant p53 In Vivo
- (2011) Y.-A. Suh et al. CANCER RESEARCH
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
- (2011) D Li et al. CELL DEATH AND DIFFERENTIATION
- Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells
- (2011) D. Li et al. MOLECULAR CANCER RESEARCH
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
- (2011) David A. Proia et al. PLoS One
- p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma
- (2010) Brendan Doyle et al. JOURNAL OF PATHOLOGY
- Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo
- (2010) Andelko Hrzenjak et al. Molecular Cancer
- Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
- (2009) J. P. Morton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss
- (2008) T. Terzian et al. GENES & DEVELOPMENT
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started